IRIS
LEMOLI, ROBERTO MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 27.848
AS - Asia 200
SA - Sud America 81
NA - Nord America 7
AF - Africa 5
Totale 28.141
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 27.844
CN - Cina 103
BR - Brasile 63
SG - Singapore 50
VN - Vietnam 40
AR - Argentina 10
US - Stati Uniti d'America 7
EC - Ecuador 4
ID - Indonesia 3
MA - Marocco 3
IQ - Iraq 2
RU - Federazione Russa 2
BD - Bangladesh 1
CL - Cile 1
CO - Colombia 1
DE - Germania 1
HK - Hong Kong 1
PY - Paraguay 1
TN - Tunisia 1
UA - Ucraina 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 28.141
Salva come PNG Salva come JPEG
Città #
Genova 16.750
Genoa 6.853
Rapallo 2.489
Vado Ligure 1.685
Bordighera 61
Beijing 45
Ho Chi Minh City 19
Hanoi 8
Singapore 7
São Paulo 7
Ashburn 3
Perugia 3
Boston 2
Da Nang 2
Hải Dương 2
Macapá 2
Salvador 2
Abaetetuba 1
Agadir 1
Araruama 1
Astorga 1
Baghdad 1
Bandung 1
Barranquilla 1
Belo Horizonte 1
Boca Toma 1
Boituva 1
Cachoeiro de Itapemirim 1
Campina Grande do Sul 1
Campos dos Goytacazes 1
Candelaria 1
Caratinga 1
Chapada Gaúcha 1
Clorinda 1
Comodoro Rivadavia 1
Conselheiro Lafaiete 1
Contagem 1
Cuenca 1
Curitiba 1
Formosa 1
Frankfurt am Main 1
Governador Valadares 1
Gresik 1
Guanhães 1
Hong Kong 1
Hortolândia 1
Itapetinga 1
Itu 1
Johannesburg 1
Joinville 1
Karbala 1
Kropyvnytskyi 1
Lorena 1
Lấp Vò 1
Maceió 1
Machala 1
Manta 1
Mariana 1
Marília 1
Medan 1
Meknes 1
Mendoza 1
Menzel Temime 1
Merlo 1
Milagro 1
Milltown 1
Montevideo 1
Morón 1
Nanuque 1
Natal 1
Ninh Bình 1
Nova Iguaçu 1
Novo Airão 1
Palhoça 1
Parauapebas 1
Pará de Minas 1
Pau dos Ferros 1
Pedra Azul 1
Phú Thọ 1
Phủ Lý 1
Porto Acre 1
Porto Alegre 1
Pouso Alegre 1
Punta Alta 1
Quilmes 1
Quảng Ngãi 1
Rabat 1
Rio de Janeiro 1
Rolândia 1
Salto 1
Santiago 1
Santo André 1
Santos Dumont 1
Saquarema 1
Sarapul 1
St Petersburg 1
Sátiro Dias 1
São Bento do Sul 1
São Caetano do Sul 1
São João Batista 1
Totale 28.023
Salva come PNG Salva come JPEG
Nome #
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 212
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes 193
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 182
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 179
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 178
T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells. 177
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 168
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 164
T lymphocyte killing by a xanthine-oxidase-containing immunotoxin. 160
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 160
Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma 160
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 155
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 155
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients 153
The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System 152
Harnessing NK Cells for Cancer Treatment 150
Viability of autologous bone marrow. 149
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 147
The sixth sense: hematopoietic stem cells detect danger through purinergic signaling. 146
C-kit ligand (SCF) in human multiple myeloma cells. 145
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. 144
Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. 143
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 143
Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies. 143
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 140
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 140
Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. 139
Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. 139
The P2X7 receptor: a key player in IL-1 processing and release. 139
CD103 Marks a Subset Of Human CD34+-Derived Langerin+ Dendritic Cells Which Induce T Regulatory Cells Via Indoleamine 2,3-Dioxygenase-1. 138
Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma 138
The CD47 pathway is deregulated in human immune thrombocytopenia. 136
Combined use of growth factors to stimulate the proliferation of hematopoietic progenitor cells after autologous bone marrow transplantation for lymphoma patients. 136
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 135
Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells 135
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. 132
A novel model of CCl4-induced cirrhosis with ascites in the mouse. 132
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 132
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 131
Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. 130
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. 129
Allogeneic hematopoietic stem cells from sources other than bone marrow: biological and technical aspects. 128
Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. 128
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 128
Megakaryocyte progenitors derived from bone marrow or G-CSF-mobilized peripheral blood CD34 cells show a distinct phenotype and responsiveness to interleukin-3 (IL-3) and PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF). 127
Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. 127
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 127
Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. 126
Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. 126
Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. 126
Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: A GITMO survey on 809 patients autografted in first complete remission 126
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 125
Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. 125
Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. 125
Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. 125
Cryopreserved autologous bone marrow transplantation in patients with acute nonlymphoid leukemia: chemotherapy before harvesting is the main factor in delaying hematological recovery. 125
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 125
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden 125
Impaired dendritic cell immunophenotype and function in heart transplant patients undergoing active cytomegalovirus infection. 124
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. 124
Interleukin-11 induces Th2 polarization of human CD4(+) T cells. 124
Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. 124
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. 123
Autologous bone marrow transplantation with marrow cryopreserved for ten years. 123
Purging in autologous and allogeneic bone marrow transplantation. 123
Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma. 122
Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma. 122
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia. 122
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 122
Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas 122
Generation and functional characterization of human dendritic cells derived from CD34 cells mobilized into peripheral blood: comparison with bone marrow CD34+ cells. 121
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 121
Characterization of autotransplant-related thrombocytopenia by evaluation of glycocalicin and reticulated platelets. 121
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial 121
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 121
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. 121
Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. 120
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. 120
Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging. 120
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 120
Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes 120
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 119
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. 119
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 119
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. 119
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 119
Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia 119
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib 119
Stem cell plasticity: time for a rappraisal? 118
Improvement of human myeloma stem cell growth in a liquid culture system supplemented with phytohemagglutinin. 118
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. 118
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 117
In vitro growth of myeloma cells. 117
Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. 117
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 117
Feasibility of Single-Port Laparoscopic Lymph Node Biopsy for Intra-Abdominal Lymphoma: A Case Series 117
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 117
Interleukin-9 in human myeloid leukemia cells. 116
Pharmacological elimination of tumor cells contaminating normal human bone marrow using PTT-119. 116
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis 116
Totale 13.341
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.302
article - articoli 89.805
book - libri 0
conference - conferenze 544
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.953
Totale 184.604
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.229 0 0 0 0 137 166 126 182 164 202 99 153
2021/20222.954 57 121 67 360 234 231 233 647 111 287 80 526
2022/20233.127 357 279 68 357 474 525 5 266 486 31 224 55
2023/20241.464 66 180 71 165 109 277 99 142 77 29 78 171
2024/20254.282 62 368 169 301 529 418 455 566 145 255 428 586
2025/20262.649 864 348 661 763 13 0 0 0 0 0 0 0
Totale 28.569